Published: On Date

Please note, this activity does not offer continuing education credit.

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Additional support for this activity provided by:

Course Description and Target Audience
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, advanced practitioners, emergency physicians and all members of the cancer team, the ACI program focuses on how to educate your patients about receiving inpatient/outpatient cellular therapies; including examples of practical implementation provided

Estimated time to complete activity: 25 Minutes

Learning Objectives
At the conclusion of this activity, the participant should be able to:

• Understand the patient journey and how to prepare a patient for these steps.

• To be informed of the many time points that require patient education and reinforcement.

• Develop an understanding about the varying pieces of education necessary for patient success.

• How to properly prepare patients and their caregivers for outpatient CAR-T cell therapy.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

Faculty and Disclosure of Conflicts of Interest

No relevant financial conflicts.

Faculty
Meaghan Ekstrom, BA, BSN, MSN, FNP-BC
Massachusetts General Hospital
Boston, MA

The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.